Good day and thank you for standing by. Welcome to the Verano Holdings Second Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you'll need to press star one on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star zero. I would now like to hand the conference over to your speaker today, Mr. Aaron Miles, Chief Investment Officer. Please go ahead. Thank you, and good morning, everyone. Welcome to Verano's Second Quarter 2021 Earnings Conference Call. I'm joined today by George Archos, Chief Executive Officer and Founder, and Brian Ward, Chief Financial Officer. During this call, we will discuss our business outlook and make forward-looking statements which are based on management assumptions and expectations. Actual events or results could differ considerably due to risks and uncertainties mentioned in our filings with SEDAR, including our financial statements and MD&A for the fiscal year ending December 31st, 2020, and our financial statements and MD&A for the three and six months ended June 30th, 2021. In addition, throughout today's discussion, Verano will refer to non-IFRS measures that do not have any standardized meaning prescribed by IFRS, such as EBITDA, adjusted EBITDA, and free cash flow. These non-IFRS measures are defined in our earnings press release issued earlier today and available at investors.verano.com, which also includes the reconciliation of these measures to the most comparable IFRS financial measures. Please note the financial information is reported on a pro forma consolidated basis as if the AltMed acquisition had closed on January 1st, 2021, compared to the actual closing which occurred on February 11th, 2021. As a point of clarification, the financial statements we filed on SEDAR are in accordance with IFRS, which includes the contribution from AltMed beginning on the day of the actual closing of February 11th versus the beginning of our fiscal year on January 1st. With that being said, results will differ between IFRS numbers filed with SEDAR and the pro forma consolidated numbers reported today. Lastly, all currency is in U.S. dollars unless otherwise noted. I'll now turn the call over to George. Please go ahead. Good morning, everyone. Thank you for joining us. I am extremely pleased with what we accomplished in the quarter, one that was instrumental relative to the foundational pieces that we've added to our portfolio to firmly establish our position as a top operator in the space and to drive long-term growth and profitability. On our last earnings call, we guided top-line revenue approaching $200 million, and we are very pleased to announce Q2 revenue of $199 million, representing 39% sequential growth, which notably did not include contribution from the Agri-Kind acquisition, which we had anticipated closing in the quarter, but instead completed in July due to regulatory delays. Overall, since going public in February, which included the closing of the transformative AltMed transaction, we have announced 11 additional acquisitions and already closed on 10. Given the combination of our unprecedented activity highlighted by significant cultivation expansion, a multitude of new dispensary openings, and most of all, substantial M&A, we expected there would be some measure of choppiness in the quarter. Despite an otherwise strong quarter as a result of our extensive activity on the M&A front, the financials we reported included some margin compression due to the one-time accounting impacts associated with integration across multiple transactions. These included significant one-time inventory markups across three high-volume dispensary groups: The Healing Center and TerraVida in Pennsylvania and Territory in Arizona, accounting for nine storefronts, which adversely impacted cost of goods sold in the quarter. In addition to inventory markups, we were subject to a negative impact of IFRS accounting treatment of our biological assets in the quarter. Through focused R&D, we've enhanced our cultivation methods, which we believe over time will increase yields while reducing plant counts and costs attendant to maintaining a higher plant count. Though we don't anticipate a near-term top-line impact from an accounting perspective, we had to absorb a steep decline in the value of our biological assets, which again adversely impacted our cost of goods sold in the quarter. Going forward, we anticipate an increase in the valuation of biological assets as new cultivation methods are deployed. We believe there is solid runway ahead of us in Pennsylvania with vertical integration coming online last month. The delayed closing of Agri-Kind not only hindered top-line performance but prevented margin expansion as it deferred our vertical benefit realization in Pennsylvania to the third quarter. Excluding the impact of these one-time accounting items and the delayed Agri-Kind closing, our margins in the quarter would have approached our signature profile. That said, the unadjusted EBITDA margin posted in our financials was 26% and 41% adjusted, which is very strong relative to industry standards. Looking ahead, we remain confident in our strategy, operations, and people, and we are incredibly optimistic about the future for Verano. We will continue to be assertive in support of our strategic vision for the company, and to close out the year, we anticipate approaching a $1.1 billion revenue runway with a margin profile nearing former levels. Turning to a more detailed review of the quarter, as I mentioned, we are very pleased to report $199 million in revenue, representing a 39% sequential lift and 164% year-over-year growth. Revenue from retail versus wholesale was 78% and 22% respectively, with retail revenues increasing 114% year-over-year, while wholesale revenues increased 29%. Verano also delivered $32 million in net income, excluding the impact of biological assets, and $81 million in adjusted EBITDA in the quarter. Our gross profit margin, excluding biological assets, was 50%. Although this is somewhat lower than we had targeted, as I highlighted a moment ago, several significant one-time events pushed margins below our signature profile for the quarter. We are confident that this compression was circumstantial, and again, anticipate closing out the year at a level closer to our signature profile. Despite the one-time impacts of the events I described, we achieved strong overall financial results while maintaining focus on strategic execution and continued growth in key markets through sound operations and disciplined capital allocation. We also made tremendous headway on several fronts while maintaining a healthy balance sheet, ending the quarter with $150 million in cash, and we remain unencumbered by sale-leaseback. In addition, as discussed in our first quarter earnings call, our financial health has been enhanced by the upsizing of our credit facility by $100 million at an industry-best 9.75% on a non-dilutive basis. We firmly believe that we will be able to meet our cash obligations going forward. Should the need arise for additional funds, we do not anticipate using dilution of our stock to raise capital. Instead, we would explore non-dilutive options such as additional debt, seeking improved terms in relation to our current facility, and we remain under-levered compared to industry standards. We have also implemented a new strategy for investment in CPG branding and product innovation through R&D, and we continue to evaluate accretive acquisition targets to further develop core geographies which are key to our long-term vision for the company. Now I'll walk you through the progress we've made in expanding our retail footprint and wholesale capacity in more detail. Starting on the retail front, our organic growth was highlighted by the opening of seven new dispensaries in the second quarter, including three in Florida, two in New Jersey, one in Pennsylvania, and a flagship storefront in the heart of Chicago. We expanded our retail footprint further through acquisition, adding nine fully operational dispensaries to our portfolio in the quarter, resulting from deals closing in Arizona and Pennsylvania. This included six storefronts in Pennsylvania between TerraVida and The Healing Center, each of which holds three of the top-performing dispensaries in Philadelphia and Pittsburgh, respectively. After Q2, we brought two additional dispensaries online in Pennsylvania and another in Florida, bringing Verano's total active retail footprint to 83 dispensaries as of today, which includes two recently announced medical recreational storefronts acquired in Reno and Carson City, Nevada, pending the close of the Sierra Well transaction. Of note, we have maximized our retail footprint in New Jersey with three locations. We are well-positioned for the onset of adult-use sales with our completed state-of-the-art 120,000 sq ft cultivation facility. Staying ahead of market growth, especially in states primed for adult-use transition, has and will remain a strength of the company. Importantly, across our retail channel, the average number of daily visits to Verano stores increased from approximately 7,000 in the second quarter of last year to more than 18,000 this quarter, with proven efficiencies based on same-store daily transaction growth of 76% year-over-year. We are currently projecting to end the year with more than 90 active dispensaries. This represents an increase from our previous approximation of 85 stores as we continue to execute exceptionally well on our retail expansion plan. We see significant opportunity for continued growth in our retail business as we enhance and refresh our brand portfolio, position ourselves for adult-use transitions in core markets such as New Jersey and Pennsylvania, and add to our retail footprint where permitted. On the wholesale front, sales were up 29% from the same period last year. We continue to invest in cultivation expansion in line with market demand and currently have 806,000 sq ft of active cultivation nationwide. In the near term, we expect our state-of-the-art multi-tier 26,000 sq ft indoor cultivation facility in Massachusetts to come online in the third quarter, where we anticipate realizing vertical benefits starting in Q4. With that, we will achieve vertical integration in nine of 11 operating markets and lift total cultivation capacity to 832,000 sq ft. Upon close of the Sierra Well deal, we will add another 10,000 sq ft to our total. Looking ahead, in West Virginia, we are one of a select few that is licensed for vertical operations, and we are taking a phased approach in building out a 40,000 sq ft cultivation facility. In Pennsylvania, we currently have 62,000 sq ft of active cultivation through our acquisition of Agri-Kind, which closed in July. As in West Virginia, we are taking a phased approach to develop a second permitted large-scale cultivation facility under the Agronomed Biologics license, providing substantial capacity expansion in the Keystone State. In Florida, we have approximately 220,000 sq ft of active cultivation, and similar to Pennsylvania, we have a second large-scale indoor facility with space for considerable expansion currently in development. Of note, following the completion of cultivation construction in Florida and Pennsylvania, we will eclipse 1 million sq ft of indoor capacity nationwide. I want to reiterate the importance of Verano's balanced strategy, driven by a focus on both retail and wholesale channels, where we anticipate the revenue split, which skewed heavily toward retail in the quarter, leveling out as we move forward. Each one not only provides an avenue for top-line growth, but our realization of vertical benefit also creates meaningful operational efficiencies, which should enable us to produce industry-leading margins upon completion of integration efforts. In limited licensed states, our wholesale presence should position us to outpace markets even after we've maximized our retail footprint, as we believe our continued investment in premium brand and product development will generate sustainable consumer demand. Turning to our investment in CPG brand strategy development and consumer experience. As market conditions evolve and the widespread adoption of adult-use cannabis policies expands addressable consumer populations considerably, we have measurably increased investment in our brand portfolio and the enhancement of our product lines. For starters, our legacy edible brand, Encore Edibles, is currently undergoing a top-down brand refresh in parallel with sweeping R&D to enhance flavors, formulas, and overall consumer experience. We anticipate a coordinated nationwide relaunch in the coming months. Similarly, we are reformulating multiple extensions of the Avexia wellness brand, including tablets and tinctures, as well as a packaging redesign. We are targeting the refreshed offering to hit retail shelves in 2022. To build on our legacy brand portfolio, meet the needs of a growing consumer base, and further secure our position in the market as a CPG leader in product development and innovation, work is underway to develop a slew of new brands, including a wellness-forward edible line geared toward millennial consumers. Across our brand portfolio, we are committed to continuous improvement in product quality and consumer experience. We continue to deploy resources on the development of proprietary flower strains, driven largely by in-house breeding. Our G-Line offering, a portfolio of cross-bred strains hinged on our top-selling cultivars, has been well-received across our footprint. With eight G-Line strains already in market and generating positive reviews, we have a roadmap for continued innovation in breeding and will introduce new strains to the market on a regular cadence going forward. As the world continues to go digital, so do the way consumers connect with brands. We are investing in a full-funnel digital ecosystem. This includes a new and much-improved Verano website that is expected to launch in Q1 next year, a long-term search engine optimization strategy to increase visibility. We are in test development stages of a custom in-house mobile app. Together, these initiatives are intended to enhance the brand experience, educate consumers, and increase awareness and engagement in the market from both novice to experienced cannabis consumers. Before I turn the call over to Brian, I want to take a moment to discuss the current U.S. regulatory environment. We are very pleased with a continued dialogue around cannabis policy reform at the federal level. We welcome these discussions, as Verano has made it a priority to be a part of the broader collective of voices helping to shape the legal framework for the future of our industry. We are committed to being a part of the process, especially as we all work together to ensure a more equitable landscape in the cannabis market. As with any change, this process will require patience, but by no means is our success or strategy dependent upon federal legalization or any other regulatory change. We believe federal legalization could create new opportunities for Verano and drive further efficiencies, but we have plenty of runway ahead of us assuming zero legislative changes. Our business has been operating and thriving for years within the current complex regulatory framework, which differs state by state, and fewer federal restrictions only provides further upside optionality to our business. We will continue to grow our operations while also actively participating in the conversations around federal legalization. While we are excited about the possibility of reform that could help us to further expand the business, deliver additional shareholder value, and create more well-paying jobs, as well as giving more back to our community, I would like to reiterate my confidence in the following statement. Our capacity to deliver on these critical functions is not at all dependent upon transformation of federal policy. With that, I will now turn the call over to Brian to provide more detail on our financials before making closing remarks. Thank you, George. It's a pleasure to speak with you all today. To start, I'll begin my remarks by reviewing financial highlights from the second quarter 2021 and then discuss our balance sheet and capital agenda. Please note, the financial information is reported on a pro forma consolidated basis as if the AltMed acquisition had closed on January 1st, 2021, compared to the actual closing, which took place on February 11th, 2021. Also, all currency is in U.S. dollars unless otherwise noted. I'm very proud of what we accomplished in the quarter from both a financial perspective and our strategic execution in building a foundation that positions us for sustainable long-term top-line growth and profitability. The industry is experiencing broad consolidation, and I believe that we are leading the pack through our efforts to add deliberate complementary assets to our portfolio at very attractive multiples. Before getting into more detail on our financials, I want to touch on our efforts to convert over to U.S. GAAP that I highlighted on the last earnings call. We have made progress as intended, and we anticipate reporting under GAAP by the end of this year. This move is significant for a couple of reasons. It better positions us to up-list to a U.S. exchange, which we believe is a matter of when, not if, and it also allows us to report under a more familiar framework, which should clean up a lot of the accounting noise that we're susceptible to reporting under IFRS. This includes the impacts George highlighted a few minutes ago, which were driven by our strength to close on multiple transactions, as well as reporting obligations associated with the valuation of our biological assets as we have implemented enhanced growing practices to lower plant count and increase yield. Both impacted our P&L during the quarter, which in a way overshadowed a fundamentally strong quarter from a margin perspective. Moving on to the financials, I'm extremely pleased to report second quarter 2021 revenue of $199 million, in line with the guidance we issued on our Q1 call. This represents growth of 39% quarter-over-quarter and 164% year-over-year, driven by positive impacts from continued investments to expand cultivation and production capacity across our wholesale footprint, dispensary openings, and contribution from closed acquisitions, excluding the potential impact from Agri-Kind, which did not close during the quarter as expected. We are also encouraged by the strong organic retail growth experienced in the quarter, with same-store sales up 13% from Q1 2021. Overall, Illinois and Florida remained our largest contributors to the top line. However, we saw an uptick in the contribution from Pennsylvania following the close of TerraVida and The Healing Center acquisitions, which added six top-performing dispensaries to our portfolio, and Arizona, which brought adult-use online earlier this year, where we added five active dispensaries through the Territory, Emerald, and Local Joint transactions. In addition, we are pleased by the progress we're making in New Jersey, Maryland, Nevada, and Ohio heading into the remainder of 2021. Before I continue highlighting our financials, I want to provide some additional color on a couple of items. First off, the IFRS accounting impacts we had to recognize during the quarter. Following the close of the Territory, TerraVida, and The Healing Center acquisitions, we had to gross up inventory from nine high-volume dispensaries, which impacted cost of goods sold by approximately $6 million in the quarter, or 3% of total revenue. Please note, this directly impacts gross profit, but we adjust this back as a one-time item in adjusted EBITDA. George also highlighted our focus on implementing new growing methods to increase yields through reduced plant counts. From an accounting perspective, and due to IFRS reporting requirements, we had to book a $25 million decline in the value of our biological assets, which of course impacted our P&L, including an additional $5.7 million that ran through COGS. This $5.7 million is not added back as a one-time item in adjusted EBITDA, and the margin erosion accounted for about 3% of total revenue. As discussed, Agri-Kind did not close in early June as we expected due to delays that were purely regulatory in nature. This impact was felt in two ways. Nearly a month of top-line revenue contribution was not realized, and we didn't unlock vertical integration in the quarter, which would have facilitated margin expansion. We estimate this negatively impacted margins by about 2%. Moving on, gross profit for the second quarter 2021 on an unadjusted basis and excluding the impact of biological assets was $100 million compared to $88 million in the prior quarter and $43 million in the same period of last year. As a percent of revenue, gross profit was 50%. When considering the approximate 8% impact that I just underscored, we would have approached our historical margin profile this quarter. Looking ahead, although we anticipate some quarterly variation and regulatory uncertainty, including in New Jersey, we expect continued margin expansion and a profile approaching historical levels to exit 2021 as we complete integration of our acquisitions, realize the benefit from investments made across our cultivation footprint, and open up additional retail doors. Looking at SG&A, we maintain a sharp focus on expense management, which has been and will remain a top priority for the company. Second quarter 2021, SG&A expense was $53 million or 27% of revenue compared to $29 million or 20% of revenue in the prior quarter. Although SG&A as a percent of revenue was elevated in comparison to prior quarters, it was driven by inclusion of multiple acquisitions and associated earn-outs, which have been added back to EBITDA as one-time adjustments. However, we've also identified operational synergies during the quarter, and as always, we'll continue working to identify additional strategic efficiencies. This methodology has been crucial to our leading expense management, which is a testament to our teams and their ability to collaborate and to streamline practices across our organization. As noted on the last call, we anticipated some fluctuation in SG&A resulting from integration and as we make investments in headcount to help propel our business as it grows. Net income in the second quarter 2021, excluding the impact of biological assets, was $32 million compared to $8 million in the first quarter 2021 and $2 million in the second quarter of 2020. Second quarter 2021 EBITDA on an unadjusted basis was $52 million or 26% of revenue compared to $60 million or 42% of revenue in the prior quarter and $24 million in the same period last year. After adjusting for one-time expenses, including inventory markups, earn-outs, and other costs related to acquisitions, adjusted EBITDA in the second quarter 2021 was $81 million or 41% of revenue compared to $75 million or 52% of revenue in the first quarter 2021 and $25 million in the same period last year. Industry-leading EBITDA margins, especially on an unadjusted basis, have been a trademark for Verano since going public. While the printed margin in the quarter didn't reach our signature profile as a company, it was impacted by the IFRS accounting measures I described earlier, the lack of contribution from vertical integration in Pennsylvania, and streamlining three substantial revenue-producing acquisitions in the quarter. As Verano continues to integrate M&A assets, including three in July, we expect some fluctuations in margins as we deploy our strategic playbook and implement leading processes. However, maintaining an industry-leading EBITDA margin is one of our top priorities, as it will allow for continued efficient funding of meaningful growth opportunities over the long term. That said, we believe that we will exit the year nearing our signature profile in unadjusted EBITDA margins. Turning to the balance sheet and cash flows, we ended the quarter with $150 million in cash and cash equivalents, which includes the previously announced $100 million upsizing of our existing credit agreement with an industry-leading 9.75% rate for a non-dilutive facility. We continue to structure M&A with a focus on efficient management of our cash position, which includes multiple payment milestones and utilizing free cash flow of the business. After June 30th, we closed on Agri-Kind, Agronomed Biologics, and Mad River Remedies. Cash consideration totaling approximately $70 million was deployed, with one delayed payment remaining in Q4 for Agri-Kind. We continue to acquire real estate through our M&A and maintain a balance sheet in advantageous condition without the hindrance of sale-leasebacks. As George mentioned, we actively manage our cash flow and feel well-positioned with our continued generation of cash. We have the ability to lever up appropriately should the opportunity for additional M&A arise and continually push for a decrease in our cost to capital. The volume of our investments in capital expenditures remains elevated as we continue to expand our infrastructure in line with experienced and anticipated growth in the market. During the quarter, our investment in capital expenditures totaled $25 million, bringing our year-to-date CapEx spend to $63 million. We expect a continuance of investment back into our business for the near term and project to close out 2021 exceeding $100 million in total CapEx. Cash flow from operations for second quarter 2021 was $29 million, and free cash flow was $4 million. This is another quarter of being able to self-fund CapEx while remaining cash flow positive, something we take tremendous pride in. Looking back at the quarter, I want to reiterate how proud I am of what we accomplished. We are moving at an expedient pace and have demonstrated a proven ability to execute at an exceptionally high level. Every action we take and every decision made is driven by our focus on building an absolute powerhouse in this industry. Before turning the call back over to George, I want to leave you with an important closing thought today. We are relentless and completely committed as an organization to grow the top line while sustaining an industry-leading margin profile. Now, I'll turn it back over to George. Before turning the call over to Q&A, I want to acknowledge the lockup of shares that expired today. We believe we have an obligation to dutifully manage the increase in liquidity of the company's shares while continuing to preserve long-term value for our employees, partners, and shareholders. After careful consideration, we opted to let the lockup expire rather than extend the potential overhang. With that, it's prudent for us to manage the manner in which our shares are released from trading restrictions, and we believe this unlock will improve liquidity and trading volume of the stock in the near term. We recognize that a lack of liquidity in our shares is to some extent limiting our stock's potential, and we are exploring options to effectively improve liquidity, which includes routine evaluation of how to most efficiently facilitate the flow of shares into the market. Speaking for myself and as the largest shareholder of the company, and I want to make this abundantly clear, I have the utmost confidence in the business and hold a long-term view of my share ownership. With that, operator, please open up the call for Q&A. Ladies and gentlemen, at this time, if you would like to ask a question, please press star followed by the number one on your telephone keypad. Again, it is star one. Your first question comes from the line of Russell Stanley with Beacon Securities. Good morning. Morning, Russ. Good morning. How are you? Good. How are you today? Good. Thank you for the breakdown around the gross margin impacts from the various events in the quarter. Maybe if I could, just more high level, tracking back to some comments I think you made during a recent fireside chat. Just wondering what you're seeing on the macro demand front with and particularly with respect to the reopening in some markets and the share of wallet shift that others have observed with consumers having more options to spend. Are you still seeing an impact in that in that regard? Did that have any impact at all in the quarter? No. I mean, we're seeing same-store sales up. Demand for us continues to grow over time as we bring new medical patient consumers online, new additional adult-use consumers, and the benefits of cannabis keep spreading. Demand keeps rising. Obviously, you know, coming off of COVID, people have options now to dine and go out and do different things, but demand for cannabis continues to grow. Great. Just moving on perhaps to Illinois, we see the lottery process is well underway to expanding the retail license base, which obviously points to a meaningful expansion in wholesale demand to your benefit. Just wondering how you're thinking about your cultivation capacity there now and what your plans might be on that front and how do you map that to when you expect the licenses to actually translate into physical demand? I would anticipate additional stores coming online more likely than not Q1 throughout the rest of next year. By the time they get through zoning, construction, et cetera, it does take some time. As far as wholesale capacity for us, we have additional capacity coming online in the back half of the year, so we feel comfortable with where we're at. We're obviously very excited for these new entrants to come into the market. It's an exciting opportunity for them. It's obviously a great opportunity for Verano to expand our wholesale business. Overall, I think it's a major positive benefit for the state and for our company. Great. Maybe if I could sneak in one last question. You still have a number of retail locations you can build out in Pennsylvania. I guess, can you provide us an update as to when you expect to be maxed out, so to speak, on the retail front in PA? We have some additional stores opening this year. We have some stores that are going through zoning. I would anticipate hopefully by summer of next year, we have all the stores open. I think that would be a fair target for us. In the Philadelphia region, zoning can be quite difficult. Timing can change, I anticipate by next summer we should have all the stores open. That's great. Excellent. Thanks for the color. I'll get back in the queue. Thanks, Russ. Have a good day. Your next question comes from the line of Kenric Tyghe with ATB Capital Markets. Thank you. Morning, Kenric. Hey. Morning, George. Chance, just a quick question. Can you first just point of clarification, you say a 200 basis point drag on Agri-Kind. A follow-up on that, can you just speak to It looked like it was a noisy quarter in Pennsylvania, just looking at some of the industry-level data on performance and growth. Can you speak to the underlying performance of the Pennsylvania market in quarter and also just provide some color around that confirmation on the margin profile change, please? Yeah, sure, Kenric. Good morning. It's Brian. You know, your first question around Pennsylvania vertical integration, that was, you know, our best estimate based on when we integrated the six stores in the quarter, as well as, you know, push the pace on the openings. With Agri-Kind closing in early July, we do believe that could have been about 200 basis points. Going forward, that's gonna be meaningful for our strategy. You know, when we look at the quarter, I think it was really strong in Pennsylvania. Continues to be a very sticky market. Basket sizes are high. You know, I would say we're pretty excited about the market as a whole. Our prospects in Pennsylvania look strong. We're excited to unlock that vertical integration, and we continue to open, you know, our stores and maximize our footprint there. Thank you, Brian. Sorry, final confirmation on this before I pivot to another question. The Agri-Kind, that was simply a regulatory related delay? Were there some other reasons why you couldn't close in quarter as expected? I mean, losing that amount side was obviously expensive, it'd be good to just better understand why. Yeah. It was mostly regulatory in nature. you know, some of these deals are hard to get to the finish line, get through all the regulatory hurdles and a lot of the legal challenges. Yeah, mostly regulatory, unfortunately. Appreciate that. Chance, if we just switch to Florida, you know, looks like you had a pretty solid performance in quarter there, particularly with respect to your sort of, you know, share of flower volume. Can you speak to, you know, how that business is tracking and performing against your own internal expectations and your level of sort of comfort around your prior guidance on store count exits, et cetera, in Florida for the year, please? Sure. I can start. Brian can take it at the end. You know, we love Florida. The AltMed transaction was obviously transformative for us. We have a phenomenal team on the ground. Everything is going as expected and actually a little bit better. That just speaks to the performance of the team. We feel very confident in exiting the year with our store count. Cultivation expansion went very well. We're ahead of schedule. We're now starting that second facility here soon. We feel very confident in our business there, both now and in the future. Thanks, George. Brian feels the same, but he doesn't need to say anything back. Yeah, 100% agree. I mean, we're gonna continue to make large-scale investments in Florida. We've got 35 open stores. We feel really excited about the prospects, not only in the market, but with our footprint. Well, that's, that's all good and fair. One quick final one, George. I know you touched on and appreciated the color on the lockups, but, you know, are there any vehicles, methods by which just you can look to help better gatekeep or the like, you know, that additional liquidity and those shares coming on? I mean, we're all well aware of what a big overhang that's been, you know, sentiment-wise and other. Are there any, you know, as I said, methods, opportunities, means by which you can gatekeep that to any extent other than the assurances provided? I mean, how do we think about this? How do we manage it, and how do we look to put this behind us as investors or rather get comfortable with it as investors either? Yeah, that's actually a good question and a fairly easy one to answer. Over 25% of our shareholders are insiders. I can tell you that I know a pretty substantial amount of the investors in our shareholder base, and most of them have a long-term view. You have to understand, we have people that have been with us for years. They believe in the company. When I make calls to see what their plans are, they all want to take the ride. This is a long-term focused company, and the shareholders that have been with us for a very long time understand that. Every decision we've made was for long-term viability of the company, and they know what the future holds. I mean, with federal legalization on the horizon, whether that's one year from now or five years from now, that's a substantial change in our business, not only for Verano, but for the entire industry. People are waiting for that. You know, and I think people will be pleasantly surprised as this unlock comes off, and we're hoping that we have some additional liquidity. We need to have additional people come into the story and that's why we didn't wanna create another overhang and add the lockups because we feel confident in our shareholder base, and more importantly, we feel confident in our business moving forward. Great. Appreciate the color. I'll get back in queue. Good luck, guys. Thanks, Kenric. Your next question comes from the line of Camilo Lyon with BTIG. Morning, guys. How are you? You know, thanks for the unpack of the puts and takes on the gross margin line. Certainly very helpful. Could you help us think about how we bridge Q2 margins and the comments around returning to the run rate profile of the business? Are we to assume that there's a steady progression back up to that level for the back half of the year, or are you kind of residing here and you'll exit that level in Q4 starting next year, kind of at that pre kind of established profile margin level? Yeah, Camilo, this is Brian. You know, we tried to unpack it the best we could. As we think about the back half of the year, we do believe we will, you know, approach our former signature margin profile. Certainly with a lot of M&A in the quarter and even to start Q3, there's gonna be a little bit of choppiness. You know, I wanna reiterate, we have not slowed down. We do envision getting gross profit, you know, towards the upper 50s and maybe even nearing 60%. Again, you know, it could be a little bit of choppiness through the quarter. There's also, you know, as we transition to GAAP, we've got New Jersey adult-use and significant CapEx. You know, those are some of the things that we're working through. Again, as we look at the back half of the year, we do think gross profit is gonna, you know, tick up towards kind of our signature levels, especially with all the cultivation coming online. You mentioned the GAAP transition. That typically has a gross margin impact. You know, I'm assuming that that's also gonna be the case for you, right? It's usually about 100 or so basis points of impact typically is what we've seen. Is that the right frame of mind to be in with the transition coming? We're still a little bit too early in our conversion process to, you know, guide or say one way or another. The one benefit we have is no sale-leasebacks. From a lease standpoint, you know, there is a benefit there. You know, with the biological impact that we didn't add back of almost 3% in the quarter, certainly if you kind of remove that, you know, our story changes in the quarter. Just on a biological basis alone relative to Q2 and going forward, we're excited for that GAAP transition. Definitely. Just wanted to make sure that we had the proper expectations set. Just switching topics, a little bit to brand positioning. Maybe, George, if you could weigh in here, I'd love your thoughts. You know, you've really done well with the Verano brand, positioning it from a premium perspective. You know, as you assess your key markets, do you see room in these markets for expanding the offerings to include a full suite of good, better, best options? If so, which are the markets that show that immediate opportunity for that strategy to unfold? We do, it really depends on supply. The good, better, best strategy is easier to deploy when you have enough supply and you have the right type of supply. It's really, we don't look at it on a national basis, we look at it on a per market, per state. As we move forward, we'll make those decisions based on the supply that we have and what makes sense for that market. That's really how we envision this playing out over the next few years. Okay. I guess then is that, would that then answer the question as to what's holding back the mix between retail and wholesale from balancing out a little bit more than it currently is? Is it really supply driven, or is there something else, more intentional in terms of trying to supply your own retail stores first with product until that supply quotient becomes more flowy, such that you have an ability to supply other wholesale doors in a bigger way? Is that what the real issue is on getting the mix of wholesale higher? Well, there's a number of different factors there, and I'll let Brian comment as well. There are certain restrictions in markets where we can't only supply our own stores, or there's a certain amount of product we can supply to our own stores. For us, brand recognition is also an important factor for us. In markets where we can supply our own stores and we can eat our own supply, the preference is to make sure that these brands are widely distributed across the state, so we build that brand recognition because we feel that that's a better long-term play. I'll pass off to Brian for his comments as well. Yeah. I mean, just a little bit of additional context is we now have Pennsylvania closed, cultivation there, along with other, you know, cultivation coming online, notably in Massachusetts, plus with a lot of the CapEx, you know, we do think wholesale is going to balance out a little bit. We can definitely be a winner in both verticals. That's just in the short term. We also have Illinois wholesale, which has great opportunity. The fact remains we keep pushing the pace in Florida, which we treat, you know, purely as retail income. Those are some of the key drivers there. We do expect a little bit more of a balance going forward. Got it. Just lastly on Florida, have you seen any sort of price, increased price competitiveness in the market? If so, where do you stand on that level of competition? Do you feel that you need to compete on price to continue to generate the throughput that you're seeing in your stores? Great question. Price is also relative to quality of the product. Right now we feel very comfortable with our business and where we stand. We're not entering that pricing competition war. We feel very comfortable with our product. We have great patient loyalty, and our business continues to expand. At some point in time, there might be a market where we deploy a more strong, good, better, best model. Right now, with what we're doing, we feel very comfortable with, and we're gonna continue down our path. Got it. Thanks very much. Good luck. No, thank you. Have a great day. Your next question comes from the line of Scott Fortune with ROTH Capital Partners. Good morning. Thanks for the questions. Real quick, outside the key states mentioned, where are we seeing with upcoming states of Massachusetts, Nevada, Ohio as you bring those on, and kind of a cadence to reach the high company margin profile that you guys are looking at as you go deeper vertically? Just kind of timing on these dates a little bit more. Right. We have cultivation. First of all, good morning, and thank you for the question. We have cultivation expansion projects in the back half of the year that'll be coming online in Florida, Illinois, Massachusetts, obviously Pennsylvania, Ohio, and Nevada. All of them are exciting projects. We've been working on them and deploying significant capital there. Out of all those, I'm really excited to see Massachusetts. It takes a long time to get your approvals done there. We should be planting that facility sometime next month, and we'll see hopefully some benefit there towards the end of Q4 into next year. We have multiple projects that are coming in the back half, and they'll add significant margin expansion for the company. Okay. I appreciate that. Thanks. Then real quick, what are you seeing on the M&A front as far as evaluations and potential strategic opportunities in new markets or going deeper in your existing markets? Kind of just touch base on kind of M&A opportunities for you guys. You know, we look at every deal. They change, they vary state by state based on the asset, what it looks like, what type of cultivation asset it is. Is it say indoor, outdoor, greenhouse, et cetera? On the retail front, is it a strong retail location? What did the prior business look like? We look at everything, but we only transact if it fits the Verano profile. We've been pretty aggressive in the M&A front. We'll continue to be, but that M&A, it has to fit our portfolio, or else it doesn't make sense. We'll continue to transact when and if it makes sense. We still have some assets that we'd like to pick up along the way, and we'll continue to look at opportunities one by one. Okay. I appreciate the color. Thanks. I'll jump in the queue. Oh, thank you. Your next question comes from the line of Andrew Semple with Echelon Capital Markets. Hi. Good morning, everyone, and congrats on the results. Good morning. Good morning. Just my first question here. Verano is very active in a number of buildouts, with production capacity expansions and new dispensary openings across several states. I'm just wondering, with respect to the construction activity underway, are you currently facing any supply shortages or cost inflation to those projects that may be cause for any delays relative to what you've signaled in the past? If you could just give us an update that, you know, everything remains on track or some states where there might be a couple months delay. Everything remains on track. Good question, by the way. There are supply issues across the country from what we hear. I do have a construction background, so we planned accordingly for all of our projects. We tend to order materials prior to any project and have them on site before we commence construction, so we don't have delays in between construction and add additional costs. We feel very comfortable with our construction schedule. I hope that answers your question. Yes, it does. Perfect. Thank you. My follow-up question, you know, you discussed in your prepared remarks, I think some pretty significant investments on the CPG side of the business, new products, new formulations, new packaging, new strains, new brands. I'm just wondering how we should be thinking about these investments in the product portfolio in relation to the financial impact for Verano. How do we tie these back to the financial performance of the business? Do you believe we can experience some improved pricing levels on these products or is it more a market share play or do you think you can get some additional cost leverage with these innovations? If you could tie that back to the financials, that would be great. Sure, Andrew. This is Brian. I mean, good question. When we think about CPG and brands, we're gonna continue to invest. You know, certainly there's gonna be some short-term costs, but as we look to the long term, we're trying to round out our portfolio, continue to enhance, go deeper with different form factors. There could be pricing opportunities, but for us it's, you know, some short-term expense for some long-term opportunity within the portfolio. It's something that we're definitely focused on. We've talked a little bit about, you know, good, better, best strategy and some other form factors that we're looking to deploy. I think it's a tremendous opportunity for this company. We've been very focused on brands now that we're at scale with, you know, 80+ dispensaries, vertical in nine states. We've got a tremendous footprint that we can deploy new products and enhance products through. Thank you, Brian, and thanks for taking my questions. Thank you. Thank you. Your next question comes from the line of Bill Papanastasiou with Canaccord Genuity. Hey, guys. Good morning. Congrats on the quarter, and thanks for taking my question. Good morning, Bill. How are you today? Good, thank you. I just wanted to talk a bit about the decriminalization and descheduling bill introduced by Chuck Schumer several weeks ago. Thanks for your prepared remarks. You know, I understand the company's success is not dependent on this bill passing, but was hoping to just gain some color on, you know, what amendments and what compromises would be needed in order to see this bill pass. I mean, it's really the same story, right? It's another positive incremental step. It's changing the minds of many, and it's happening slowly but surely. Do I think the bill happens or passes this year? Most likely not. Again, it's on the forefront, it's on people's minds, and we could see something on the banking side, we could see something on decrim side. I don't think full legalization is in the near term going to happen. These are things that need to happen in order for something to happen in the future. We view it as another positive incremental step. That's really how we look at it. It's the same thing we've been saying for years. It's a matter of when, not if, and we're just looking forward to more steps to a final solution. Okay, great. Thank you. That's all the questions I have. Thank you. Your final question comes from the line of Neal Gilmer with Haywood Securities. Yeah, good morning, guys. Congrats on the quarter. Many of the questions have been asked, but maybe two sort of small ones. One was just sort of to see if you could give a little bit more clarity on the timing of those expansions in Pennsylvania and Florida. Is that sort of a mid 2022 that they come online and start contributing there? To follow up on some of your comments to a previous question on sort of your M&A philosophy. Obviously, you've done a bunch since you've gone public and closed most of them. As you look forward, your message previously and continues to be going deeper, you look at your sort of retail footprint sort of getting up towards some of the limits in various states. You know, are you looking more at trying to build out or acquire more cultivation-type assets, and that would sort of help bring that mix between the retail and wholesale a little bit closer together? Thanks. Yeah, good question. On PA and Florida, I expect most likely the back half of 2022 is when we'll see some change in our financials. These projects take time to really come to fruition, and by the time you plant and harvest and cure, et cetera, I see more of a Q3, Q4 benefit in 2022 on those two markets. As far as on the M&A front, it really, it's a per market basis. We'd like to be vertical in the majority of our markets. Right now, we're getting very close. We still have to deploy our M&A strategy. There're some other things. We have some loose ends we like to tie up in our footprint, and we'll start looking outside of it if and when it makes sense. Something we've been very vocal about. We look at every deal, but it has to fit the Verano profile. We're in no rush to grow our footprint. It just has to be the right deal at the right time for us. Okay, great. Thank you. Thank you. Have a great day. Thank you for joining, everyone. We're looking forward to the Q3 call. We appreciate everyone's time today. Ladies and gentlemen, this does conclude today's conference. You may now disconnect.